Related Experiment Video
Updated: Mar 19, 2026
Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
RNA splicing factors as oncoproteins and tumour suppressors
Heidi Dvinge1,2, Eunhee Kim3, Omar Abdel-Wahab3,4
1Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Abstract:
The recent genomic characterization of cancers has revealed recurrent somatic point mutations and copy number changes affecting genes encoding RNA splicing factors. Initial studies of these 'spliceosomal mutations' suggest that the proteins bearing these mutations exhibit altered splice site and/or exon recognition preferences relative to their wild-type counterparts, resulting in cancer-specific mis-splicing. Such changes in the splicing machinery may create novel vulnerabilities in cancer cells that can be therapeutically exploited using compounds that can influence the splicing process. Further studies to dissect the biochemical, genomic and biological effects of spliceosomal mutations are crucial for the development of cancer therapies targeted at these mutations.
Insights
Genomic studies reveal cancer-driving mutations in RNA splicing factors. These spliceosomal mutations cause cancer-specific mis-splicing, creating vulnerabilities that may be targeted by new cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Genomic characterization of cancers has identified recurrent somatic mutations in RNA splicing factor genes.
- These mutations, termed 'spliceosomal mutations,' alter the function of RNA splicing machinery.
Purpose of the Study:
- To investigate the functional consequences of spliceosomal mutations in cancer.
- To explore the potential of targeting these mutations for cancer therapy.
Main Methods:
- Genomic characterization of cancer samples.
- Biochemical and functional assays to assess splicing factor activity.
- Analysis of mis-splicing events in cancer cells.
Main Results:
- Spliceosomal mutations lead to altered splice site and exon recognition preferences.
- Cancer-specific mis-splicing patterns are observed in cells with these mutations.
- These alterations may confer unique vulnerabilities to cancer cells.
Conclusions:
- Spliceosomal mutations represent a distinct class of cancer-driving alterations.
- Targeting the splicing process offers a potential therapeutic strategy for cancers with these mutations.
- Further research is needed to fully understand the biochemical and biological impact of these mutations for therapeutic development.
Related Concept Videos
01:32RNA Splicing
01:32RNA Splicing
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:12Loss of Tumor Suppressor Gene Functions